Mark Kotter, University of Cambridge

Sure, Bit Bio got some sig­nif­i­cant cash for its cell cod­ing work. But it’s the in­sid­ers who are back­ing them that will gar­ner the at­ten­tion

Mark Kot­ter’s syn­thet­ic bi­ol­o­gy team at Bit Bio has al­ready won lots of lo­cal recog­ni­tion in the UK for its tech for pre­ci­sion re­pro­gram­ming of stem cells at an in­dus­tri­al scale. Now they have a jolt of cash from some mar­quee US in­vestors to fu­el the work and dri­ve some added glob­al panache for the biotech’s pro­file.

The mon­ey — $41.5 mil­lion — isn’t like­ly to stir much at­ten­tion these days as bil­lions in cash con­tin­ue to course through the in­dus­try. These in­vestor names, though, as well as their in­ter­est in cell ther­a­py 2.0, should cre­ate a tin­gle of ex­cite­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA